PURPOSE: This study was conducted to reappraise the efficacy of redo-Kasai (or revision) in the era of liver transplantation as a treatment option in those patients with recurrent jaundice after initially successful Kasai procedure. METHODS: We studied ten patients that received redo-Kasai, among a total of 102 patients diagnosed with biliary atresia after receiving Kasai operation from 1986 to 2011. RESULTS: Kasai operation was done at a median age of 55 days and redo-Kasai at 150 days. The bilirubin levels returned to normal in six patients after the procedure. Four of six enjoyed jaundice-free survival with native liver till the time of last follow-up. Three patients died and three received liver transplantation (LT). Only one out of seven patients with three or more episodes of cholangitis survived with native liver, while all the three patients with 1 or 0 episode survived with native liver. The difference was significant (P = 0.033). Re-do Kasai did not result in more blood loss or operative time during LT. CONCLUSION: Redo-Kasai is still valuable in the era of LT and the episodes of cholangitis are the decisive factors affecting the outcome of the procedure.
PURPOSE: This study was conducted to reappraise the efficacy of redo-Kasai (or revision) in the era of liver transplantation as a treatment option in those patients with recurrent jaundice after initially successful Kasai procedure. METHODS: We studied ten patients that received redo-Kasai, among a total of 102 patients diagnosed with biliary atresia after receiving Kasai operation from 1986 to 2011. RESULTS: Kasai operation was done at a median age of 55 days and redo-Kasai at 150 days. The bilirubin levels returned to normal in six patients after the procedure. Four of six enjoyed jaundice-free survival with native liver till the time of last follow-up. Three patients died and three received liver transplantation (LT). Only one out of seven patients with three or more episodes of cholangitis survived with native liver, while all the three patients with 1 or 0 episode survived with native liver. The difference was significant (P = 0.033). Re-do Kasai did not result in more blood loss or operative time during LT. CONCLUSION: Redo-Kasai is still valuable in the era of LT and the episodes of cholangitis are the decisive factors affecting the outcome of the procedure.
Authors: Riccardo Superina; John C Magee; Mary L Brandt; Patrick J Healey; Greg Tiao; Fred Ryckman; Frederick M Karrer; Kishore Iyer; Annie Fecteau; Karen West; R Cartland Burns; Alan Flake; Hanmin Lee; Jeff A Lowell; Pat Dillon; Paul Colombani; Richard Ricketts; Yun Li; Jeffrey Moore; Kasper S Wang Journal: Ann Surg Date: 2011-10 Impact factor: 12.969
Authors: Alexander J Bondoc; Janice A Taylor; Maria H Alonso; Jaimie D Nathan; Yu Wang; William F Balistreri; Jorge A Bezerra; Frederick C Ryckman; Gregory M Tiao Journal: Ann Surg Date: 2012-03 Impact factor: 12.969
Authors: Barbara E Wildhaber; Pietro Majno; Johannes Mayr; Zacharias Zachariou; Judith Hohlfeld; Marcus Schwoebel; Walter Kistler; Martin Meuli; Claude Le Coultre; Gilles Mentha; Dominique Belli; Christophe Chardot Journal: J Pediatr Gastroenterol Nutr Date: 2008-03 Impact factor: 2.839